Holen Sie sich die Stockscreener-App
36.43
0.64%
0.23
Schlusskurs vom Vortag:
$36.20
Offen:
$36.44
24-Stunden-Volumen:
2.20M
Relative Volume:
0.95
Marktkapitalisierung:
$10.40B
Einnahmen:
$2.08B
Nettoeinkommen (Verlust:
$466.92M
KGV:
23.35
EPS:
1.56
Netto-Cashflow:
$404.94M
1W Leistung:
+2.19%
1M Leistung:
+9.43%
6M Leistung:
+61.19%
1J Leistung:
+62.06%
1-Tages-Spanne:
$35.91
$36.90
1-Wochen-Bereich:
$35.91
$37.59
52-Wochen-Spanne:
$20.02
$37.59
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Vergleichen Sie EXEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
36.43 | 10.40B | 2.08B | 466.92M | 404.94M | 1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
What Makes Exelixis (EXEL) an Investment Bet? - Insider Monkey
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Hennion & Walsh Asset Management Inc. - MarketBeat
Exelixis sets 2025 guidance in line with estimates - MSN
Should You Be Adding Exelixis (NASDAQ:EXEL) To Your Watchlist Today? - Yahoo Finance
EXEL (Exelixis) Long-Term Debt & Capital Lease Obligation : $194 Mil (As of Sep. 2024) - GuruFocus.com
Exelixis (NASDAQ:EXEL) Given New $41.00 Price Target at Oppenheimer - MarketBeat
FY2024 EPS Estimates for Exelixis Increased by Analyst - MarketBeat
Institutional investors control 74% of Exelixis, Inc. (NASDAQ:EXEL) and were rewarded last week after stock increased 5.9% - Simply Wall St
Tallon Kerry Patrick Invests $2.62 Million in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis price target raised to $41 from $38 at Oppenheimer - MSN
Oppenheimer bullish on Exelixis stock as cabo sales and R&D progress impress - MSN
Exelixis's SWOT analysis: cabozantinib drives growth as stock faces ip challenges - Investing.com India
Exelixis stock hits 52-week high at $36.98 amid robust growth - Investing.com Nigeria
Exelixis (NASDAQ:EXEL) Hits New 52-Week High on Analyst Upgrade - MarketBeat
15 Analysts Have This To Say About Exelixis - Benzinga
Exelixis (NASDAQ:EXEL) Stock Price Expected to Rise, JMP Securities Analyst Says - MarketBeat
Burney Co. Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
FY2025 EPS Estimates for Exelixis Lifted by William Blair - MarketBeat
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance
Exelixis stock hits 52-week high at $36.98 amid robust growth By Investing.com - Investing.com South Africa
Exelixis: Truist raises price target citing increased sales potential - Investing.com
Long Term Trading Analysis for (EXEL) - Stock Traders Daily
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again - MSN
FY2024 EPS Estimates for Exelixis Lifted by William Blair - MarketBeat
Exelixis Provides Preliminary 2024 Results and Outlook for 2025 - MSN
Exelixis says no FDA AdCom for Cabometyx label expansion - MSN
Exelixis (NASDAQ:EXEL) Price Target Raised to $37.00 at Piper Sandler - MarketBeat
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025 - BioSpace
Exelixis Reports Strong $1.8B Revenue for 2024, Projects Growth in 2025 with New Cancer Drug Expansion - StockTitan
FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib - MSN
Exelixis (NASDAQ:EXEL) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza (EXEL) - Seeking Alpha
Exelixis Inc. Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (Cabometyx®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors - Marketscreener.com
Exelixis Notified by FDA That Cabozantinib Application Won't Be Discussed at Meeting - Marketscreener.com
Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX - Business Wire
Range Financial Group LLC Purchases New Holdings in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis (NASDAQ:EXEL) Given New $42.00 Price Target at Guggenheim - MarketBeat
Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth? - MSN
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 - Business Wire
Exelixis CEO to Present Corporate Strategy at J.P. Morgan Healthcare Conference 2025 - StockTitan
Exelixis, Inc. (NASDAQ:EXEL) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
How the (EXEL) price action is used to our Advantage - Stock Traders Daily
JPMorgan Chase & Co. Trims Position in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis price target raised to $38 from $34 at RBC Capital - Yahoo Finance
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):